Buspirone Can Be Stopped Abruptly When Starting Lexapro
Buspirone (Buspar) does not require tapering and can be discontinued abruptly when initiating escitalopram (Lexapro). Unlike benzodiazepines or SSRIs themselves, buspirone has no significant withdrawal syndrome even after prolonged use.
Evidence for Abrupt Discontinuation
The safety of abrupt buspirone discontinuation is well-established:
Long-term studies demonstrate no withdrawal syndrome: Research involving 424 patients treated for 6 months and 264 patients for a full year showed that abrupt discontinuation of buspirone after more than 6 months of therapy yielded "no evidence of a withdrawal syndrome or unusual events" 1.
Controlled discontinuation studies confirm this finding: A comparative trial of buspirone versus lorazepam found that after 8 weeks of treatment, buspirone-treated patients were "free from withdrawal symptoms" when treatment was abruptly stopped, while lorazepam-treated patients experienced symptom worsening 2. Another controlled study using the Lader tranquilizer withdrawal scale showed minimal withdrawal effects with buspirone compared to benzodiazepines 3.
Important Safety Consideration: Serotonin Syndrome Risk
While buspirone can be stopped abruptly, the FDA label for Lexapro specifically warns about serotonin syndrome risk when combining escitalopram with buspirone 4. The label cautions about "concomitant use of Lexapro with other serotonergic drugs including...buspirone" and instructs patients to contact their healthcare provider if they experience signs or symptoms of serotonin syndrome.
Practical Approach
Given these considerations:
- Stop buspirone on the same day you start Lexapro - no taper is needed
- Monitor closely for serotonin syndrome during the transition period (first 1-2 weeks), watching for: agitation, confusion, rapid heart rate, dilated pupils, muscle rigidity, tremor, sweating, or fever
- The concern is not about withdrawal from buspirone, but rather about the brief overlap period if both medications are present
Context from Depression Treatment Guidelines
The clinical trial evidence supports this approach. In the STAR*D study, when citalopram (closely related to escitalopram) failed as initial treatment, augmentation with buspirone showed similar efficacy to other strategies 5, 6. However, discontinuation due to adverse events was significantly higher with buspirone (20.6%) compared to bupropion (12.5%) 5, suggesting tolerability issues rather than withdrawal concerns.
Key Pitfall to Avoid
Do not confuse buspirone with SSRIs or benzodiazepines regarding discontinuation. SSRIs like escitalopram itself require careful tapering to avoid discontinuation syndrome 7, 8, but buspirone does not share this pharmacological property. The Buspar FDA label makes no mention of required tapering 9, in stark contrast to SSRI labels which emphasize gradual dose reduction.